Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Autor: Sibylle Boehmer, Lars Franzén, Robert E. Coleman, Joe M. O'Sullivan, Rui Li, Steffen Wedel, Isabel Syndikus, John P Logue, Mihalj Seke, David Bottomley, Ales Chodacki, Oliver Sartor, Daniel Heinrich, Sophie D. Fosså, Nicholas D. James, Marcos F. Dall'Oglio, Paweł Wiechno, K. Staudacher, Sten Nilsson, Peter Hoskin, Arne Solberg, Nicholas J. Vogelzang, Oana Petrenciuc, Svein Inge Helle, Anders Widmark, Ján Kliment, Øyvind S. Bruland, Dag Clement Johannessen, Chris Parker
Rok vydání: 2018
Předmět:
Zdroj: Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology, vol. 73, pp. 427-435 . https://doi.org/10.1016/j.eururo.2017.06.021
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Translational Andrology and Urology
Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology . https://doi.org/10.1016/j.eururo.2017.06.021
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2017.06.021
Popis: BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.OBJECTIVE: To report updated ALSYMPCA safety, including long-term safety up to 3 yr after the first injection.DESIGN, SETTING, AND PARTICIPANTS: Safety analyses from phase 3 randomized ALSYMPCA trial included patients receiving ≥1 study-drug injection (600 radium-223 and 301 placebo). Patients (405 radium-223 and 167 placebo) entered long-term safety follow-up starting 12 wk after the last study-drug injection, to 3 yr from the first injection. Forty-eight of 405 (12%) radium-223 and 12/167 (7%) placebo patients completed follow-up, with evaluations every 2 mo for 6 mo, then every 4 mo until 3 yr.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All adverse events (AEs) were collected until 12 wk after the last injection; subsequently, only treatment-related AEs were collected. Additional long-term safety was assessed by development of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, and secondary malignancies. Data analysis used descriptive statistics.RESULTS AND LIMITATIONS: During treatment to 12 wk following the last injection, 564/600 (94%) radium-223 and 292/301 (97%) placebo patients had treatment-emergent AEs (TEAEs). Myelosuppression incidence was low. Grade 3/4 hematologic TEAEs in radium-223 and placebo groups were anemia (13% vs 13%), neutropenia (2% vs 1%), and thrombocytopenia (7% vs 2%). Ninety-eight of 600 (16%) radium-223 and 68/301 (23%) placebo patients experienced grade 5 TEAEs. Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in four radium-223 and three placebo patients. One radium-223 patient had aplastic anemia 16 mo after the last injection. No other cases were observed. Limitations include short (3-yr) follow-up.CONCLUSIONS: Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns.PATIENT SUMMARY: Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection.
Databáze: OpenAIRE
Externí odkaz: